10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“practice guidelines increasingly recognize the prevention of ischemic events as a key management priority.5,6”
In the citing paper
“However, subsequent trials that specifically examined the role of a blood pressure lowering strategy to <130 mm Hg in patients with T2DM and hypertension found no substantive benefit of intensive blood pressure control in reducing the risk of coronary events, although there was evidence for decreased risk of stroke.5,66–69”
In the citing paper
“As such, while all patients with T2DM and CAD certainly benefit from a blood pressure of <140/90 mm Hg,5,63–66,76”
In the citing paper
“ACE inhibitors/ARBs reduce the progression of kidney disease in patients with albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g)5 and reduce the risk of both incident and recurrent atherosclerotic ischemic events.79,80”
In the citing paper
“Furthermore, fibrates or fish oil would be indicated when triglycerides are very high (>500 mg/dL) to reduce the risk of pancreatitis.5”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Research works printed but not linked: 2
- American College of Obstetricians and Gynecologists’, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
- Fitchett, 2017, Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial, Eur Heart J, 39, 363, 10.1093/eurheartj/ehx511 · DOI · Paper page
Cited by
Items 201–300 of 470
Bachmann, K. N., Roumie, C. L., Wiese, A. D., Grijalva, C. G., Buse, J. B., Bradford, R. L., Zalimeni, E., Knoepp, P., Dard, S., Morris, H., et al. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.637 · Cited by 13
Cardiovascular Outcome Trials with Glucose-Lowering Drugs
Thethi, T. K., Bilal, A., & Pratley, R. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01505-3 · Cited by 11
Yang, S., Shen, W., Zhang, H.-Z., Wang, C., Yu, W., & Wu, Q. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001364 · Cited by 14
Visit Entropy Associated with Diabetic Control Outcomes
Dilger, B. T., Gill, M. C., Lenhart, J. G., & Garrison, G. M. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.05.190026 · Cited by 11
Bazarbashi, N., & Miller, M. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1749596 · Cited by 11
Andersson, T., Pikkemaat, M., Schiöler, L., Hjerpe, P., Carlsson, A. C., Wändell, P. E., Manhem, K., Kahan, T., Hasselström, J., & Boström, K. B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237107 · Cited by 12
Bugiardini, R., Pavasović, S., Yoon, J., van der Schaar, M., Kedev, S. A., Vavlukis, M., Vasiljević, Z., Bergami, M., Miličić, D., Manfrini, O., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100548 · Cited by 13
Schroeder, E. B., Neugebauer, R. S., Reynolds, K., Schmittdiel, J. A., Loes, L., Dyer, W., Pimentel, N., DESAI, J. R., Vazquez‐Benitez, G., Ho, P. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.26605 · Cited by 11
Boswell, L., Serés‐Noriega, T., Mesa, A., Perea, V., Pané, A., Viñals, C., Blanco, J., Giménez, M., Vinagre, I., Esmatjes, E., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01959-z · Cited by 12
Greenwood, J. D., Zurek, K. I., Grimm, J. M., Wi, C., Vogel, J. T., & Garrison, G. M. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.10.001 · Cited by 13
Sharma, A., Deyell, J., Sharma, S. N., & Barseghian, A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1168-y · Cited by 10
Yang, R., Bai, J., Fang, Z., Wang, Y., Feng, Y., Liu, Y., Chi, H., Deng, Y., Song, Q., & Cai, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14927 · Cited by 10
Vincent, R., Kim, J., Ahmed, T., & Patel, V. V. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190018824820 · Cited by 12
Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence
Al‐Sofiani, M. E., Derenbecker, R., Quartuccio, M., & Kalyani, R. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1206-6 · Cited by 13
Shen, J. I., Nicholas, S. B., Williams, S., & Norris, K. C. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1251-4 · Cited by 10
Rocca, B., Rubboli, A., & Zaccardi, F. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880045 · Cited by 12
Marx, N., Rydén, L., Brosius, F. C., Ceriello, A., Cheung, M., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108092 · Cited by 10
Raghavan, S., Liu, W. G., Berkowitz, S. A., Barón, A. E., Plomondon, M. E., Maddox, T. M., Reusch, J. E. B., Ho, P. M., & Caplan, L. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05848-5 · Cited by 9
Lan, N. S. R., Chan, D. C., Pang, J., Fegan, P. G., Yeap, B. B., Rankin, J. M., Schultz, C. J., Watts, G. F., & Bell, D. A. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.932 · Cited by 11
Aspirin for Primary Stroke Prevention; Evidence for a Differential Effect in Men and Women
Gdovinová, Z., Kremer, C., Lorenzano, S., Dawson, J., Lal, A., & Caso, V. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.856239 · Cited by 16
Conte, C., Maggiore, U., Cappelli, G., Ietto, G., Lai, Q., Salis, P., Marchetti, P., Piemonti, L., Secchi, A., Capocasale, E., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.004 · Cited by 10
Khunti, K., HERTZ, C. L., Husemoen, L. L. N., Mocevic, E., Nordsborg, R. B., Piltoft, J. S., & Bain, S. C. (2021) · Diabetic Medicine · doi:10.1111/dme.14697 · Cited by 10
Chen, C., Gao, H., Wei, Y., & Wang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1511701 · Cited by 11
“Furthermore, DM is a recognized risk factor for coronary artery disease and is a leading cause of cardiovascular disease and mortality among patients (Association, 2019; Baena-Diez et al., 2016).”
Jun, J. E., Jeong, I., Ahn, K. J., Chung, H. Y., & Hwang, Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109044 · Cited by 10
Feng, X., Gu, Q., Gao, G., Yuan, L., Li, Q., & Zhang, Y. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.07.1113 · Cited by 11
Dézsi, C. A., Глезер, М. Г., IuA, K., Brzozowska-Villatte, R., & Farsang, C. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01527-3 · Cited by 9
García-Ulloa, A. C., Lechuga-Fonseca, C., Razo-Olvera, F. M. D., Aguilar-Salinas, C. A., Galaviz, K. I., Narayan, K. M. V., & Hernández-Jiménez, S. C. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001891 · Cited by 11
Luchsinger, J. A., Younes, N., Manly, J. J., Barzilay, J. I., Valencia, W. M., Larkin, M., Falck-Ytter, C., Krause-Steinrauf, H. J., Pop‐Busui, R., Florez, H. J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2858 · Cited by 12
Wu, S., Ye, Y., Peng, L., Chen, Y.-M., Zeng, F., Zhuo, S.-Y., Lu, W., 卢伟, Chen, P., Mai, H., et al. (2022) · Nutrients · doi:10.3390/nu14091713 · Cited by 11
Olomu, A. B., Kelly‐Blake, K., Hart-Davidson, W., Gardiner, J. C., Luo, Z., Heisler, M., & Holmes-Rovner, M. M. (2022) · Trials · doi:10.1186/s13063-022-06581-6 · Cited by 13
Abdel‐Rahman, N., Calderon‐Margalit, R., Cohen, A. D., Elran, E., Golan‐Cohen, A., Krieger, M., Paltiel, O., Valinsky, L. J., Ben‐Yehuda, A., & Manor, O. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025603 · Cited by 10
Shubrook, J. H., Pak, J., & DAILEY, G. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01405-y · Cited by 9
Olesen, K. K. W., Madsen, M., Gyldenkerne, C., Thrane, P. G., Thim, T., Jensen, L. O., Bøtker, H. E., Sørensen, H. T., & Mæng, M. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01212-x · Cited by 10
Body adiposity markers and insulin resistance in patients with type 1 diabetes
Marques, C. L., Beretta, M. V., Prates, R. E., de Almeida, J. C., & Rodrigues, T. D. C. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000599 · Cited by 9
Mustafar, R., Hishamuddin, K. A. M., Mohd, R., Kamaruzaman, L., Halim, W. H. W. A., Hsien, Y. M., Sze, T. K., Zaki, W. M. D. W., Ali, A., & Bain, A. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03386-w · Cited by 10
“In short, these findings support the fact that proteinuria is a known risk factor for ASCVD [31].”
BackgroundBarkmeier, A. J., Deng, Y., SWARNA, K. S., Herrin, J. S., Polley, E. C., Umpierrez, G. E., Galindo, R. J., Ross, J. S., Mickelson, M. M., & McCoy, R. G. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.07.019 · Cited by 13
Ena, J., Carretero‐Gómez, J., Zapatero, A., Carrasco-Sánchez, F. J., Romero-Sánchez, M., González-Becerra, C., Blázquez-Encinar, J. C., Igúzquiza-Pellejero, M. J., Yangüela, B. D. E., Gómez‐Huelgas, R., et al. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2019.12.009 · Cited by 8
Le, Y., Yang, J., Li, F., Jiang, Y., Wei, T., Wang, D., Wang, K., Cui, X., Lin, X., Yang, K., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3607 · Cited by 8
Wang, L., Zhang, W., Dai, J., Deng, Q., Yan, Y., & Liu, Q. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14196 · Cited by 11
“The risk of adverse events increased when FPG levels deviated from the optimal range, which is consistent with previous studies 10,11,17,18 .”
ResultRana, K., Reid, J., Rosenwasser, J. N., Lewis, T., Sheikh‐Ali, M., Choksi, R. R., & Goldfaden, R. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s167375 · Cited by 8
Thongtang, N., Piyapromdee, J., Tangkittikasem, N., Samaithongcharoen, K., Srikanchanawat, N., & Sriussadaporn, S. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s219496 · Cited by 10
Herold, Z., Herold, M., Lohinszky, J., Dank, M., & Somogyi, A. (2020) · Cancers · doi:10.3390/cancers12030556 · Cited by 8
Napoli, R., Formoso, G., Piro, S., Targher, G., Consoli, A., & Purrello, F. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.07.012 · Cited by 9
Παπάνας, Ν., Elisaf, M., Kotsa, K., Melidonis, A. J., Bousboulas, S., Bargiota, Α., Pagkalos, E., Doupis, J., Ioannidis, I., Avramidis, I., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00935-6 · Cited by 10
Okada, S., Morimoto, T., Ogawa, H., Soejima, H., Matsumoto, C., Sakuma, M., Nakayama, M., Doi, N., Jinnouchi, H., Waki, M., et al. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06167-5 · Cited by 8
Feng, K. Y., Li, J., Ianus, J., de Zeeuw, D., Fulcher, G., Pfeifer, M. A., Matthews, D. R., Jardine, M., Perkovic, V., Neal, B. C., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14525 · Cited by 8
Kwon, H., Song, K. H., Yu, J. M., Kim, D. S., Shon, H. S., Ahn, K. J., Choi, S. H., Ko, S., Kim, W. B., Lee, K. H., et al. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20137 · Cited by 10
Марущак, М. І., Kozak, K., & Krynytska, І. (2022) · Endocrine Regulations · doi:10.2478/enr-2022-0018 · Cited by 10
Tecce, N., Masulli, M., Palmisano, L., Gianfrancesco, S., Piccolo, R., Pacella, D., Bozzetto, L., Massimino, E., Pepa, G. D., Lupoli, R., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110001 · Cited by 11
Lee, M. M. Y., & Sattar, N. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15085 · Cited by 11
Ni, K., Yang, J. Y., Baeg, K. J., Leiter, A., Mhango, G., Gallagher, E. J., Wisnivesky, J. P., & Kim, M. K. (2021) · Cancer Reports · doi:10.1002/cnr2.1387 · Cited by 8
Picard, F. A., & Steg, P. G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00919-2 · Cited by 8
Dou, Y., Chen, B., Yu, X., & Ma, D. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.04.004 · Cited by 7
Bose, D., Maurya, M. R., & Konwar, M. (2023) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_342_21 · Cited by 9
“[1] They inhibit the reuptake of glucose and sodium in the proximal convoluted tubule of the kidney.”
InfluentialGuo, L., Zhang, B., Hou, J., & Zhou, Z. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00869-z · Cited by 8
Inglin, L., Lavikainen, P., Jalkanen, K., & Laatikainen, T. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-02077-6 · Cited by 10
Aspirin for Primary Prevention of Cardiovascular Disease
Kim, J. H., Shim, M. J., Lee, S., Oh, J., & Kim, S. H. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.162 · Cited by 8
Potassium binding for conservative and preservative management of chronic kidney disease
Clegg, D. J., & Palmer, B. F. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000564 · Cited by 8
Tan, J. W. C., Sim, D., Ako, J., Almahmeed, W. A., Cooper, M. E., Dalal, J. J., Deerochanawong, C., Huang, D. W. C., Johar, S., Kaul, U., et al. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.52 · Cited by 8
Risk factors for nephropathy in persons with type 1 diabetes: a population-based study
Ahmadi, S. S., Pivodic, A., Svensson, A., Wedel, H., Rathsman, B., Nyström, T., Ludvigsson, J., & Lind, M. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01863-6 · Cited by 9
Mohammed, M. S., & Ahmed, H. S. (2023) · Journal of Cardiovascular and Thoracic Research · doi:10.34172/jcvtr.2023.32895 · Cited by 8
Sarkar, S., Orimoloye, O. A., NASS, C. M., Blumenthal, R. S., & Martin, S. S. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05266-2 · Cited by 7
Tsujimoto, T., & Kajio, H. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13886 · Cited by 6
Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis
Kuo, W., Stevens, J. M., Ersig, A. L., Johnson, H. M., Tung, T., & Bratzke, L. C. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00843-x · Cited by 8
Марущак, М. І., Vivsiana, I., Musiienko, V., Krynytska, І., & Kozak, K. (2021) · Acta Clinica Croatica · doi:10.20471/acc.2021.60.03.20 · Cited by 11
What is new in lipid‐lowering therapies in diabetes?
Cheung, Y.-M. M., O’Brien, R., & Ekinci, E. I. (2019) · Internal Medicine Journal · doi:10.1111/imj.14291 · Cited by 8
BAJAJ, H. S., Brown, R. E., Jiandani, D., Venn, K., Al‐Asaad, H., Khandwala, H. M., Steen, O., Abdel‐Salam, S., & Aronson, R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14084 · Cited by 7
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07744-8 · Cited by 8
“These agents are recommended as first-line therapy by the American Diabetes Association and the European Society of Cardiology for patients with diabetes and underlying cardiovascular disease [4, 5].”
Yan, P., Luo, Y., Zhang, J., Liu, H., Chen, J., Wang, J., Dong, G., & Ge, M. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14630 · Cited by 6
Mohammed, M. S., & Ahmed, H. S. (2023) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_832_23 · Cited by 7
Cui, X.-Y., Liu, T., Bai, Y.-L., Zhang, M.-D., Li, G., Zhang, Y., Yuan, Y., Zhang, Y.-W., Yu, L., Han, L., et al. (2024) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-024-3658-z · Cited by 6
Nørgaard, C. H., Starkopf, L., Gerds, T. A., Malmborg, M. W., Bonde, A. N., Zareini, B., Mills, E. H. A., Vestergaard, P., Wong, N. D., Torp-Pedersen, C. T., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108126 · Cited by 5
Zhou, Z., Zheng, M., Zuo, Z., & Wu, T. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14726 · Cited by 5
Xu, W., Li, X., Tse, G., Chan, J. S. K., Wu, S., & Liu, T. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102737 · Cited by 6
Lan, N. S. R., Fegan, P. G., Yeap, B. B., Rankin, J. M., & Watts, G. F. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13689 · Cited by 6
Management of type 2 diabetes: now and the future
Edeghere, S., & English, P. (2019) · Clinical Medicine · doi:10.7861/clinmed.2019-0318 · Cited by 6
Liday, C., & Kirkpatrick, C. F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1232-7 · Cited by 6
Cicci, J. D., Iyer, P. S., Clarke, M. M., & Mazzella, A. J. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000297 · Cited by 5
Bae, J., Lee, Y., Kang, E. S., Soo, B., & Lee, B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010136 · Cited by 7
Mohan, A., Vadhariya, A., Majd, Z., Esse, T. W., Serna, O., & Abughosh, S. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2020.12.009 · Cited by 6
Meiring, S., Busch, C. B. E., van Baar, A. C. G., Hemke, R., Holleman, F., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01628-z · Cited by 8
Keyvanshokooh, E., Zhalechian, M., Shi, C., Oyen, M. P. V., & Kazemian, P. (2025) · Management Science · doi:10.1287/mnsc.2019.03211 · Cited by 19
Aspirin in primary prevention: the triumph of clinical judgement over complex equations
Santilli, F., & Simeone, P. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02191-4 · Cited by 6
Fan, M., Stephan, A., Emmert-Fees, K. M. F., Peters, A., & Laxy, M. (2023) · Diabetologia · doi:10.1007/s00125-023-05950-3 · Cited by 8
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
Gao, Y., Fan, C., Tan, X., Zhang, J., & Wang, J. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103450 · Cited by 5
Cardiovascular outcome trials of glucose-lowering therapies
Khunti, K., Davies, M. J., & Seidu, S. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1763796 · Cited by 7
Cohen, C. M., Hallén, N., Chodick, G., Bourvine, L., Waner, T., & Karasik, A. (2020) · Value in Health Regional Issues · doi:10.1016/j.vhri.2020.05.003 · Cited by 7
Histone modification as a potential preventative and therapeutic approach for cardiovascular disease
Habibian, J. S., & Ferguson, B. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816422-8.00014-3 · Cited by 6
Raghavan, S., Ho, Y.-L. A., Vassy, J. L., Posner, D. C., Honerlaw, J. P., Costa, L., Phillips, L. S., GAGNON, D. R., Wilson, P. W. F., & Cho, K. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006528 · Cited by 4
Viktorínová, A., Fábryová, Ľ., Malickova, D., Choudhury, S., & Krizko, M. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0087 · Cited by 6
Gastrointestinal Bleeding Risk Factors in Patients with Type 2 Diabetes Mellitus
Kı̇şı̇oğlu, S. V., Habiboğlu, İ., Günay, Y., Durak, S., Karakullukçu, S., & Fidan, S. (2022) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2022.01.15 · Cited by 5
Yamaji, T., Harada, T., Kajikawa, M., Maruhashi, T., Kishimoto, S., Yusoff, F. M., Chayama, K., Goto, C., Nakashima, A., Tomiyama, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64416 · Cited by 6
Górriz, J. L., Cos, X., Duque, N., & Matalí, A. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.07.001 · Cited by 5
Perspectives on the role of exercise in the treatment of pediatric type 1 diabetes
Ilkowitz, J. T., Wu, F., Chen, Y., & GALLAGHER, M. P. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12965 · Cited by 5
Camm, A. J., & Atar, D. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1721665 · Cited by 6
Mitochondrial oxidants promote platelet activation and thrombotic susceptibility in prediabetes
Ahmed, A., Yadav, P., Jensen, M., Geasland, K. M., Swamy, J., Spitz, D. R., Abel, E. D., Jalal, D. I., & Dayal, S. (2025) · Journal of Clinical Investigation · doi:10.1172/jci195662 · Cited by 7
Baldissera, S., Minardi, V., Masocco, M., & Ferrante, G. (2022) · European Journal of Public Health · doi:10.1093/eurpub/ckac037 · Cited by 4
Rodríguez‐Gutiérrez, R., Flores-Rodríguez, A., Raygoza-Cortez, K., García-Leal, M., Mariño-Velasco, S., Plata-Huerta, H. H., Sáenz-Flores, M., Ramírez-García, L. A., Rojo‐Garza, A., Maraka, S., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03159-9 · Cited by 3
Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure
Sharma, A., & Ezekowitz, J. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.08.012 · Cited by 4
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S103-S123
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4213222556
- Semantic Scholar
- b0a37d21ada65be89484f4b750bf45f281a7f7c5
- Cited by
- 471
- References
- 172
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 20 · 2023: 35 · 2022: 65 · 2021: 84 · 2020: 134 · 2019: 109
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiovascular disease, cardiovascular risk management, diabetes mellitus, clinical guidelines, quality of care, treatment goals, level of evidence
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Humans, Risk Management, Societies, Medical, United States, Practice Guidelines as Topic, Diabetic Cardiomyopathies, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.